LOX-1, a bridge between GLP-1R and mitochondrial ROS generation in human vascular smooth muscle cells

Biochemical and Biophysical Research Communications

Volumn 437, Issue 1, 2013, Pages 62-66

  Dai, Yao ^a,b   Mercanti, Federico ^a   Dai, Dongsheng ^b   Wang, Xianwei ^a   Ding, Zufeng ^a   Pothineni, Naga Venkata ^a   Mehta, Jawahar L ^a  

^a CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^b ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

GLP 1; LOX 1; Ox LDL; ROS

Indexed keywords

COMPLEMENTARY DNA; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; LIRAGLUTIDE; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

GLP-1; LOX-1; OX-LDL; ROS;

ANIMALS; AORTA; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FLUORESCENCE; GENE DELETION; GLUCAGON-LIKE PEPTIDE 1; HUMANS; LIPOPROTEINS, LDL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MITOCHONDRIA; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; REACTIVE OXYGEN SPECIES; RECEPTORS, GLUCAGON; SCAVENGER RECEPTORS, CLASS E;

MUS;

EID: 84880514665     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.06.035     Document Type: Article

References (24)

1. Mitra S., Goyal T., Mehta J.L. Oxidized LDL, LOX-1 and atherosclerosis. Cardiovasc. Drugs Ther. 2011, 25:419-429.
2. Ding Z., Wang X., Khaidakov M., et al. Degradation of heparan sulfate proteoglycans enhances oxidized-LDL-mediated autophagy and apoptosis in human endothelial cells. Biochem. Biophys. Res. Commun. 2012, 426:106-111.
3. Dai Y., Su W., Ding Z., et al. Regulation of MSR-1 and CD36 in macrophages by LOX-1 mediated through PPAR-γ. Biochem. Biophys. Res. Commun. 2013, 431:496-500.
4. Wang X., Phillips M.I., Mehta J.L. LOX-1 and angiotensin receptors, and their interplay. Cardiovasc. Drugs Ther. 2011, 25:401-417.
5. Deacon C.F. Therapeutic strategies based on glucagon-like peptide 1. Diabetes 2004, 53:2181-2189.
6. Garber A.J. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care 2011, 34:S279-284.
7. Cariou B. Harnessing the incretin system beyond glucose control: potential cardiovascular benefits of GLP-1 receptor agonists in type 2 diabetes. Diabetes Metab. 2012, 38:298-308.
8. Egom E.E. A therapeutic approach to hyperglycaemia in the setting of acute myocardial infarction: spotlight on glucagon-like peptide 1. Ther. Adv. Cardiovasc. Dis. 2012, 6:213-219.
9. Sivertsen J., Rosenmeier J., Holst J.J., et al. The effect of glucagon-like peptide 1 on cardiovascular risk. Nat. Rev. Cardiol. 2012, 9:209-222.
10. Shigeta T., Aoyama M., Bando Y.K., et al. Dipeptidyl peptidase-4 modulates left ventricular dysfunction in chronic heart failure via angiogenesis-dependent and -independent actions. Circulation 2012, 126:1838-1851.
11. Li N., Li B., Brun T., et al. NADPH oxidase NOX2 defines a new antagonistic role for reactive oxygen species and cAMP/PKA in the regulation of insulin secretion. Diabetes 2012, 61:2842-2850.
12. Kappe C., Holst J.J., Zhang Q., et al. Molecular mechanisms of lipoapoptosis and metformin protection in GLP-1 secreting cells. Biochem. Biophys. Res. Commun. 2012, 427:91-95.
13. Mukai E., Fujimoto S., Sato H., et al. Exendin-4 suppresses SRC activation and reactive oxygen species production in diabetic Goto-Kakizaki rat islets in an Epac-dependent manner. Diabetes 2011, 60:218-226.
14. Erdogdu O., Eriksson L., Xu H., et al. Exendin-4 protects endothelial cells from lipoapoptosis by PKA, PI3K, eNOS, p38 MAPK, and JNK pathways. J. Mol. Endocrinol. 2013, 50:229-241.
15. Mehta J.L., Sanada N., Hu C.P., et al. Deletion of LOX-1 reduces atherogenesis in LDLR knockout mice fed high cholesterol diet. Circ. Res. 2007, 100:1634-1642.
16. Lu J., Wang X., Wang W., et al. LOX-1 abrogation reduces cardiac hypertrophy and collagen accumulation following chronic ischemia in the mouse. Gene Ther. 2012, 19:522-531.
17. Hu C., Dandapat A., Sun L., et al. Modulation of angiotensin II-mediated hypertension and cardiac remodeling by lectin-like oxidized low-density lipoprotein receptor-1 deletion. Hypertension 2008, 52:556-562.
18. Metz R.P., Patterson J.L., Wilson E. Vascular smooth muscle cells: isolation, culture, and characterization. Methods Mol. Biol. 2012, 843:169-176.
19. Wang X., Khaidakov M., Ding Z., et al. Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) and cardiac fibroblast growth. Hypertension 2012, 60:1437-1442.
20. Kröller-Schön S., Knorr M., Hausding M., et al. Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition. Cardiovasc. Res. 2012, 96:140-149.
21. Lu J., Mitra S., Wang X., et al. Oxidative stress and lectin-like ox-LDL-receptor LOX-1 in atherogenesis and tumorigenesis. Antioxid. Redox Signaling 2011, 15:2301-2333.
22. Morgan M.J., Liu Z.G. Crosstalk of reactive oxygen species and NF-κB signaling. Cell Res. 2011, 21:103-115.
23. Shiraki A., Oyama J., Komoda H., et al. The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells. Atherosclerosis 2012, 221:375-382.
24. Lu J., Wang X., Wang W., et al. Abrogation of lectin-like oxidized LDL receptor-1 attenuates acute myocardial ischemia-induced renal dysfunction by modulating systemic and local inflammation. Kidney Int. 2012, 82:436-444.